LOGIN  |  REGISTER
Recursion
Chimerix

Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

October 16, 2023 | Last Trade: US$33.21 0.22 0.67
  • Helps support faster diagnosis, enabling earlier treatment of eye conditions
  • Enables a more digitally connected primary care exam
  • Facilitates collaboration and education among primary care clinicians, specialists, patients and family members

DEERFIELD, Ill. / Oct 16, 2023 / Business Wire / Baxter International Inc. (NYSE:BAX), a leader in patient monitoring, physical assessment and vision screening products, announced the launch of digital image capture capability for eye exams using its existing Welch Allyn PanOptic Plus Ophthalmoscope. The iExaminer Pro System adds a key technology to routine eye exams, designed to help advance healthcare professionals’ ability to examine and diagnose the eye health of patients.

“Healthcare settings have never been more demanding, and clinicians need their tools to offer improved efficiency and accuracy that ultimately allows earlier care for patients,” said Jim O’Connell, president, Front Line Care, Baxter. “The iExaminer Pro System uses the latest tech, allowing providers to spend more time focusing on the thing that matters most – their patients.”

The PanOptic Plus Ophthalmoscope with iExaminer Pro System adds the ability to connect a smart device to capture images for further examination and enables clinicians to move quickly from an optical exam to adding digital image capture. When used with the iExaminer Pro App, clinicians can securely save and share eye images for tracking and trending and initiate more informed consultations with specialists.

“Examining the structure of the eyes is a critical part of assessing patient health,” said Julie Jakubowski, M.D., F.A.C.P., head of medical affairs, Front Line Care, Baxter. “The PanOptic Plus Ophthalmoscope with iExaminer Pro System helps to enable healthcare providers to catch issues early on in a primary care setting, easily collaborate with specialists, and facilitates patients getting the diagnosis, care and treatment they need in a timely manner.”

The iExaminer Pro System has been in use with Baxter’s Welch Allyn MacroView Plus Otoscope since 2021. The addition of digital image capture capability for eye exams represents the company’s continued commitment to using connected devices to help improve patient outcomes via routine physical exams.

The PanOptic Plus and MacroView Plus tools offer clinicians bigger views compared to standard ophthalmoscopes and otoscopes, plus additional key features such as long-lasting LED lamps and DuraShock technology for durability.

The new offering is now available in the U.S. and will be showcased at the upcoming American Academy of Pediatrics National Conference & Exhibition (Oct. 20-24) and American Academy of Family Physicians Family Medicine Experience conference (Oct. 26-29). Find more information and the full range of product capabilities here.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release includes forward-looking statements concerning potential benefits associated with the Welch Allyn PanOptic Plus Ophthalmoscope with iExaminer Pro System. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter, DuraShock, iExaminer Pro, MacroView Plus, PanOptic Plus and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB